Bispecific Antibody Provides Durable Remission in Myeloma
REGN5459, designed to deplete plasma cells while mitigating the cytokine release syndrome, demonstrated deep and durable clinical responses in heavily pretreated relapsed/refractory myeloma.
Source: medscape.com